Kamdar Names Potential Treatment Options Beyond Liso-cel in R/R LBCL

Results from the long-term follow-up study (NCT03435796) based on the phase 3 TRANSFORM trial (NCT03575351) were presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition, assessing lisocabtagene maraleucel (liso-cel; Breyanzi) vs standard-of-care therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL).

Data showed a median overall survival that was not reached (NR) and a median progression-free survival that was NR (95% CI, 12.6-NR) with liso-cel in the second line of therapy vs 6.2 months (95% CI, 4.3-8.6) in the standard of care arm. These results were observed across first, second, and third-line options.

Manali Kamdar, MD, spoke with CancerNetwork® at ASH to discuss these results. She highlighted what subsequent treatment options may look like for patients with LBCL who progress after initial treatment with liso-cel.

Kamdar is the clinical director of Lymphoma Services at the University of Colorado Anschutz School of Medicine.

Transcript:

That’s a very important question, and something that we are currently trying to improve upon for patients who progress after having received liso-cel or after having received CAR T-cell therapy. There are a lot of constructs that are currently being investigated, but probably the one that comes to mind, also in terms of what the regulatory agencies have approved, would be CD20 bispecific T-cell engagers. Primarily, glofitamab[-gxbm; Columvi] and epcoritamab[-bysp; Epkinly] got their FDA label, [and the studies] did include 30% of patients with prior CAR T-cell therapy progression. These are the patients who did show a response.

It’s important to tease out, though, that patients who are refractory demonstrated less [of a] response to subsequent CD20 bispecific T-cell engagers than patients who had relapsed post-treatment in the past. There is a lot more that needs to be done. With that, we are here at ASH trying to figure out the next best in line treatment for this class.

Reference

Kamdar M, Solomon S, Arnason J, et al. Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM. Blood. 2025;146(suppl 1):3710. doi.10.1182/blood-2025-3710